Pipeline
Robust Asset Pipeline Setting Up Potential for Long Term Growth
Nasus Pharma is advancing a portfolio of powder-based intranasal therapies designed to address life-threatening emergencies. Our proprietary Nasax® platform delivers rapid, reliable absorption and predictable pharmacokinetics, creating opportunities across multiple acute indications.
Drug Candidate
Molecule
Indication
Preclinical
Phase 1
Phase 2
Pivotal Trial
Next Milestone
NS002
Epinephrine
Anaphylaxis
Preclinical
Phase 1
Phase 2
Pivotal Trial
Phase 2 single dose PK study completed in March 2023
Results from Phase 2 repeated dose study expected Q1 26
NS003
Ondansetron
Nausea and Vomiting
Preclinical
Phase 1
Phase 2
Pivotal Trial
Preclinical
FIH study H2/26
NS004
Undisclosed
Metabolic
Preclinical
Phase 1
Phase 2
Pivotal Trial
Preclinical
FIH study H2/26
NS005
Undisclosed
Cardiovascular
Preclinical
Phase 1
Phase 2
Pivotal Trial
Preclinical
TBD
NS001*
Naloxone
Opioid overdose
Preclinical
Phase 1
Phase 2
Pivotal Trial
Pivotal Phase 3 completed (n=42)
Available for partnering
NS001: Naloxone
NS001 is engineered for rapid opioid overdose reversal, providing faster and higher systemic drug levels than standard liquid sprays. The needle-free portable design ensures timely life-saving intervention.
NS002: Epinephrine
NS002 treats anaphylaxis, achieving superior early exposure and rapid therapeutic onset compared with injectable alternatives. Phase 2 data highlight predictable pharmacokinetics and strong intranasal absorption.